MacroGenics Announces Pricing of Public Offering of Common Stock

MacroGenics (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the pricing of an underwritten public offering of 4,500,000 shares of its common stock at a public offering price of $21.25 per share, before underwriting discounts and commissions.

As quoted in the press release:

Leerink Partners, Deutsche Bank Securities and Evercore Group L.L.C. are acting as joint book-running managers of the proposed offering. Stifel, Nomura and SunTrust Robinson Humphrey are acting as lead managers and H.C. Wainwright & Co. is acting as co-manager. The offering is expected to close on or about April 2, 2018, subject to customary closing conditions.

MacroGenics anticipates the total gross proceeds from the offering (before deducting underwriters’ discounts and commissions and estimated offering expenses) will be approximately $95.6 million, excluding any exercise of the underwriters’ option to purchase additional shares.

Click here to read the full press release.